BCR-ABL1, Minor (p190), Quantitative

2005016
copy
 

Copy Utility


emailprint
Example Reports
Detected
Enhanced Report
Not Detected

Icon

Time Sensitive

Icon

Additional Technical Information
Ordering Recommendation

Order in cases of Philadelphia chromosome positive (Ph+) lymphoblastic leukemia to quantify the BCR-ABL1 p190 fusion form. For CML, use BCR-ABL1, Major (p210), Quantitative, (2005017).

Mnemonic
BCR MIN
Methodology

Quantitative Reverse Transcription Polymerase Chain Reaction

Performed

RNA isolation: Sun-Sat
Assay: Sun, Tue, Thu

Reported

5-7 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA) or bone marrow (EDTA). Also acceptable: RNA extracted by CLIA certified lab.

Specimen Preparation

Whole Blood: Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Transport 3 mL bone marrow. (Min: 1 mL)
Specimens must be received within 48 hours of collection due to lability of RNA.
Extracted RNA: Transport 40 uL RNA with at least 40 ng/uL concentration. (Min: 40 uL) Transport RNA in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.

Storage/Transport Temperature

Whole Blood or Bone Marrow: CRITICAL REFRIGERATED. Separate specimens must be submitted when multiple tests are ordered.
Extracted RNA: CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.

Unacceptable Conditions

Serum, plasma, CSF, extracted DNA, RNA extracted by a non-CLIA lab, bone core, or FFPE tissue. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed or clotted specimens.

Remarks
Stability

Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable
Extracted RNA: Ambient: Unacceptable; Refrigerate: Unacceptable; Frozen: Indefinitely

Reference Interval
Interpretive Data

Refer to report.

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

For p210 fusion form (major breakpoint), order BCR-ABL1, Major (p210), Quantitative (ARUP test code 2005017).

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
08/19/2019
X
N/A
CPT Codes

81207

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
0051095 BCR-ABL1, t(9;22) Source 31208-2
2005007 BCR-ABL1, Minor (p190) Result 21823-0
2005008 BCR-ABL1/ABL1, Minor (p190) Quant Ratio 52132-8
2005009 EER BCR-ABL1, Minor (p190) 11526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • p190
  • PH1
  • philadelphia chromosome
  • Philadelphia MS
  • t(9;22)
BCR-ABL1, Minor (p190), Quantitative